Ribobio's BD Team Wins '2024 Influential Business Development Award' Amid Hong Kong IPO Filing

On December 17, 2024, the "6th China Biomedical Industry Chain Innovation and Transformation Forum, the 1st Guangdong-Hong Kong-Macao Greater Bay Area Biomedical Industry Innovation and Transformation Forum, and the 5th China Biomedical Industry Chain Innovation Annual Ceremony 2024" was grandly held. Ribo Life Science's BD team won the "Business Development of the Year Award" for its outstanding performance in the BI and Qilu Pharmaceutical licensing deal projects.

      China Biomedical Industry Chain Innovation Ranking

"China Biomedical Industry Chain Innovation Top List" is led by Academician Kai-Xian Chen and initiated by the China Biomedical Industry Chain Innovation and Transformation Consortium (CBIITA Consortium). Since 2020, it has been consecutively evaluated for five sessions. The selection adheres to the aim of "setting industry benchmarks, stimulating innovation potential, and fostering an innovation ecosystem," using authoritative data for multi-dimensional analysis and multi-perspective verification, integrating objective data with expert wisdom. It has become a benchmark award in the field of biomedical industry innovation and transformation. Ribo Life Science's receipt of this honor not only represents the organizing committee’s high recognition of the company’s outstanding achievements in business development but also highlights its technical strength and industry status in the small nucleic acid drug field.